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Abstract
Background: Detachment of photoreceptors from the underlying retinal pigment epithelium is seen in various retinal
disorders such as retinal detachment and age-related macular degeneration and leads to loss of photoreceptors and vision.
Pharmacologic inhibition of photoreceptor cell death may prevent this outcome. This study tests whether systemic
administration of tauroursodeoxycholic acid (TUDCA) can protect photoreceptors from cell death after experimental retinal
detachment in rodents.
Methodology/Principal Findings: Retinal detachment was created in rats by subretinal injection of hyaluronic acid. The
animals were treated daily with vehicle or TUDCA (500 mg/kg). TUNEL staining was used to evaluate cell death.
Photoreceptor loss was evaluated by measuring the relative thickness of the outer nuclear layer (ONL). Macrophage
recruitment, oxidative stress, cytokine levels, and caspase levels were also quantified. Three days after detachment, TUDCA
decreased the number of TUNEL-positive cells compared to vehicle (651668/mm
2 vs. 1314668/mm
2, P=0.001) and
prevented the reduction of ONL thickness ratio (0.8460.03 vs. 0.6560.03, P=0.002). Similar results were obtained after 5
days of retinal detachment. Macrophage recruitment and expression levels of TNF-a and MCP-1 after retinal detachment
were not affected by TUDCA treatment, whereas increases in activity of caspases 3 and 9 as well as carbonyl-protein adducts
were almost completely inhibited by TUDCA treatment.
Conclusions/Significance: Systemic administration of TUDCA preserved photoreceptors after retinal detachment, and was
associated with decreased oxidative stress and caspase activity. TUDCA may be used as a novel therapeutic agent for
preventing vision loss in diseases that are characterized by photoreceptor detachment.
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Introduction
Photoreceptor loss occurs acutely after retinal detachment.
Although surgery is performed for rhegmatogenous retinal
detachment the visual acuity of patients is not always restored
after successful reattachment surgery. [1–3] In other retinal
disorders including age-related macular degeneration and diabetic
retinopathy, retinal photoreceptor detachment persists chronically
and vision loss progresses for many patients. [4,5] Studies in
humans and in experimental animal models have demonstrated
that after detachment of the retina, the photoreceptors begin to
degenerate and die over time. [6–8] Therefore, therapeutic agents
targeting photoreceptor death may improve treatment for retinal
disorders associated with retinal detachment.
TUDCA is a minor component of human bile and a primary
constituent of bear bile. [9,10] Bear bile has been used in Chinese
medicine for ophthalmic and hepatic indications for over 3000
years. [9,10] Recently, researchers have tested TUDCA and
related bile acids for biological activity using modern scientific
methods. The related drug, ursodeoxycholic acid (UDCA) -also
known as Actigall, Urso, or Ursodiol- reduces liver damage in the
setting of cholestasis and has been approved by FDA for the
treatment of primary biliary cirrhosis. TUDCA itself has been
demonstrated to show cytoprotective effects in a variety of
experimental systems including several models of neurodegener-
ative diseases [11–17] as well as against light-induced or oxidative
stress-induced retinal damage in mice and mouse model of retinitis
pigmentosa. [9,18,19]
This study tests whether the systemic administration of
tauroursodeoxycholic acid (TUDCA) can protect photoreceptors
from cell death after experimental retinal detachment. We show
that this agent has neuroprotective effects, associated with
inhibition of apoptosis and decrease in oxidative stress, thereby
exhibiting potential as a novel neuroprotective therapeutic drug in
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detachment.
Results
TUDCA prevents photoreceptor death after retinal
detachment
First, we assessed photoreceptor death after retinal detachment
by TUNEL staining, which detects DNA fragmentation in
apoptotic or necrotic nuclei. [20] Intraperitoneal administration
of TUDCA (500 mg/Kg/day) significantly reduced the numbers
of TUNEL-positive cells in outer nuclear layer (ONL) three days
(651668 mm
2 vs 1314668 mm
2 in control group, P=0.001) and
five days (243.4623.9 mm
2 vs 393.7614.4 mm
2 in control group,
P=0.04) after retinal detachment (Fig. 1B).
Then we investigated the ability of systemically administered
TUDCA to preserve ONL thickness after retinal detachment
(Fig. 1C and 1D). The standardized ratio of ONL to total thickness
in detached versus attached areas was measured and compared
betweenvehicleand TUDCAtreatedgroups.A ratioof1represents
no loss of ONL thickness, while ratios less 1 than represent loss of
ONL thickness. After three days of detachment, the ONL thickness
ratio of the vehicle-treated group decreased to 0.6560.03, while
TUDCA significantly prevented the reduction of ONL thickness
ratio (0.8460.03, P=0.0016, Fig 1C). Five days after detachment,
the ratio in the vehicle treatedgroups was 0.5760.04 whereas in the
TUDCA treated group it remained higher at 0.7960.03
(P=0.002). Administration of TUDCA six hours after the induction
of RD also showed efficient neuroprotection (P=0.03; Fig. 1D).
TUDCA does not affect TNF-a, MCP-1 or CD68+ cell
infiltration
We have shown previously that inflammatory cytokines and
macrophage infiltration are markedly elevated in experimental
RD. [21–23] Similar to those studies, increased levels of TNF-a,
MCP-1 and CD68+ cell infiltration were noted after retinal
detachment but were not altered by TUDCA treatment (Fig. 2).
TUDCA reduces protein oxidization by reactive oxygen
species (ROS)
TUDCA has been proven to exert cytoprotective effects in
different models by reducing oxidative stress. [19,24] We have also
previously shown that retinal detachment leads to increased ROS
Figure 1. Systemic TUDCA administraton decreases photoreceptor cell loss in RD.( A) DAPI (blue) and TUNEL (green) staining of attached
or detached for 5 days retina sections. TUDCA treatment was started 24 hrs before RD induction and continued daily at a dose of 500 mg/kg/day. (B)
Quantitative analysis of TUNEL positive cells 3 and 5 days after RD with or without daily TUDCA treatment (500 mg/kg/day, I.P.). (n=6, p,0.05). (C)
Quantitative data exhibiting the protective effect of TUDCA (500 mg/kg/day, I.P.) on ONL thickness preservation, 3 and 5 after RD. (n=6, p,0.05). (D)
Protective effects of TUDCA were seen even when TUDCA treatment was started 6 hours after RD induction. (n=6, P,0.05).
doi:10.1371/journal.pone.0024245.g001
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[23,25] One day after retinal detachment, TUDCA treatment
completely prevented the increase in the amount of protein
carbonyls after retinal detachment (Fig. 3).
The neuroprotective effects of TUDCA are associated
with decreased caspase activation
Caspases have previously been shown to play a role in retinal
detachment. [26,27] The cytoprotective effects of TUDCA were
also investigated by measuring activity of caspases 2, 3, 8, 9 and
11, which includes pathway members from both the intrinsic and
the extrinsic pathway. TUDCA administration significantly
decreased retinal detachment-induced activity for Caspases 2, 3
and 9 (P,0.05), while it did not alter the increases in Caspase 8
and 11 (Fig. 4 and 5).
TUDCA does not significantly decrease Endoplasmic
reticulum (ER) stress after retinal detachment
Prolonged ER stress can lead to cell death. Recently Liu et al.
[35] have shown that proapoptotic ER stress proteins such as
growth arrest DNA damage-inducible gene 153 (GADD153) also
known as C/EBP homologous protein [28], is increased after RD
in rats. Additionally, in isolated rat pancreatic acini TUDCA has
been shown to decrease ER stress and downregulate CHOP
expression [36]. We thus evaluated the effect of TUDCA on
CHOP expression after RD. Even though RD increased the levels
of CHOP, systemic TUDCA administration did not have a
significant effect on this elevation (Figure 5).
Discussion
Hydrophilic bile acids like UDCA and TUDCA had been
empirically used for ophthalmic indications in traditional Chinese
medicine for thousands of years. [9,10] Recently they have been
studied more systematically and have been shown to be
cytoprotective in experimental models of neurodegenerative
diseases, including Huntington’s disease [11,12], Alzheimer’s
disease [13], Parkinson’s disease [14] and hemorrhagic stroke.
[15,16] In mice, TUDCA also protects photoreceptors against
light-induced retinal damage and from a genetic mutation that
models retinitis pigmentosa. [9,18,19]
In this study, we demonstrate that systemic administration of the
hydrophilic bile acid TUDCA has photoreceptor neuroprotective
effects in an experimental retinal detachment model and in
agreement with studies by others, where TUDCA has been shown
to mediate its cytoprotective effects partially through inhibition of
caspase mediated apoptosis. [29–31] The neuroprotective effect of
Figure 2. TUDCA did not diminish the inflammatory response after RD. ELISA for TNF-a (A) and MCP-1 (B) levels 1 day after RD. TUDCA was
administered as in Figure 1. Immunostaining (C) and quantification (D) for infiltrating CD68+ cells (green) 1 day after RD. Nuclei were counterstained
with DAPI (blue) TUDCA was administered as in Figure 1 (A) (n=6, P.0.05).
doi:10.1371/journal.pone.0024245.g002
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detachment was correlated with inhibition of caspases 2, 3 and 9
and a decrease in TUNEL- positive cells. Daily TUDCA
administration reduced the number of TUNEL positive cells by
about 50% and reduced the loss of ONL thickness by a similar
amount initially but the effect becomes less pronounced on day 5.
This could be the result of the existence of alternative mechanisms
of cell loss in retinal detachment as was recently described by our
group. [28] It has been shown by others and us that TUNEL
staining is not restricted to apoptotic cells but encompasses
necrotic cells as well. [20,28] It is possible that TUDCA is not
effective in blocking both apoptotic and necrotic pathways that are
activated upon RD and thus the protection offered by it may be
limited.
Inflammation is thought to play a significant role in retinal
detachment mediated photoreceptor cell loss. Several studies have
shown upregulation of inflammatory cytokines such as TNF-a and
MCP1 [32,33] and have demonstrated increased infiltration of
macrophages. [34] However, we showed that TUDCA did not
affect the inflammatory cytokine production measured in total
retina homogenates (it could affect the leukocyte MCP content)
and did not alter the inflammatory cell infiltration after retinal
detachment. Consistent with our findings, a study on hepatocytes
showed that TUDCA did not affect the levels of the TNF-a
released from Kuppfer cells isolated from the liver [32] while
another study found that TUDCA protected hepatocytes from
TNF-a induced death. [35] In a study of isolated biliary epithelial
cells TUDCA did not alter the levels of IL-6 or MCP1 secretion.
[36] These data suggest that the cytoprotective action of TUDCA
may be mediated through a direct effect on damaged cells rather
than through regulation of inflammatory processes.
Endoplasmic Reticulum (ER) stress has been shown to be a
feature in various neurodegenerative disorders, [37] as well as in
retinal detachment. [38] Persistent ER stress leads to pro-apoptotic
molecule induction such as growth arrest DNA damage-inducible
gene 153 (GADD153) also known as C/EBP homologous protein
[28]. In a study of isolated pancreatic acini it was shown that
TUDCA decreased ER stress and CHOP expression. [36] Similar
to the previous study of ER stress in RD [35] we found that RD
lead to increased levels of CHOP (Fig. 5) but in contrast to the
pancreatic acini study TUDCA did not significantly alter its
expression. In line with this finding, TUDCA did not decrease
Caspase 11 induction, a downstream effector of CHOP.
The related drug UDCA has been shown to inhibit changes in
mitochondrial transmembrane potential and ROS generation in
isolated mitochondria from the liver of adult rats. [39] Oxidative
stress is a factor playing a critical role in photoreceptor death after
RD and we have shown that ROS reduction is associated with
neuroprotective effect on photoreceptors after RD. [15,23,25]
Administration of TUDCA led to almost complete abolishment of
the increase in protein carbonyl content, a measure of ROS levels.
Hence, a combination of the inhibition of caspases and decrease in
the ROS levels could be partially responsible for the neuropro-
tective mechanism of TUDCA in the RD model.
The exact mechanism TUDCA protects photoreceptor cells
remains unknown and its effects may be direct or indirect. Given
the limited effect on inflammatory cytokines and infiltrating
leukocytes, it seems that the inflammatory cell may not be a major
target of TUDCA -at least not in this model. Thus, it seems that a
direct effect on photoreceptor cells is more likely. This may also
partially explain why the delayed administration of TUDCA lead
to reduced efficiency since bioavailability of TUDCA to the outer
retina is expected to be impaired after photoreceptor separation
from the tissues supplying them with nutrients (RPE and choroid).
Although a previous study reported that systemic administration
of TUDCA (500 mg/kg/day) in a model of retinitis pigmentosa
had negative impact on the weight gain of developing mice, [18]
there was no effect on the weight of adult rats in our study. This
could be because our animals were already adults when treatment
was started. In fact, the similar non-taurine conjugated UDCA
does not show any significant adverse effects given to humans for
extended period of time- up to 2 years- to treat liver diseases, and
has been approved by the FDA. These findings suggest that
TUDCA is an efficient and safe neuroprotective agent and may
have a therapeutic potential for patients suffering from diseases
where retinal degeneration is involved.
Photoreceptor loss and subsequent visual decline occurs when
the photoreceptors are separated from the underlying retinal
pigment epithelium. Physical separation of photoreceptors is seen
in various retinal disorders, including retinal detachement as well
as age-related macular degeneration [4] and diabetic retinopathy
[5]. The visual acuity of patients with rhegmatogenous retinal
detachment is not always restored, even after successful operation
for reattachment. Two fifths of patients with rhegmatogenous
retinal detachment involving the macula, a region essential for
central vision recover 20/40 or better vision because of
photoreceptor death. [40,41] Thus, identification of neuroprotec-
tive agents preventing photoreceptor loss may open a novel
approach for treatment of these diseases. The findings of this study
Figure 3. TUDCA diminishes oxidative stress after RD. Levels of
protein carbonyl adducts can be used as an index of exposure to
oxidative stress. The increase in the protein carbonyl concentration
24 hours after RD as measured by ELISA, was completely reversed with
TUDCA treatment (administered as in Figure 1 (A), n=6, p,0.05).
doi:10.1371/journal.pone.0024245.g003
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approach for preventing vision deficit in various retinal disorders
associated with photoreceptor loss.
Methods
Animals
All animal experiments adhered to the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research, and the
protocols were approved by the Animal Care Committee of the
Massachusetts Eye and Ear Infirmary. Adult male Brown Norway
rats (Charles River, Wilmington, MA) weighing 200–250 g were
fed standard laboratory chow and allowed free access to water in
an air-conditioned room with a 12 h light/12 h dark cycle.
Retinal Detachment Induction
Rats were anesthetized with 100 ml of a mixture of 5 parts
Ketamine (100 mg/ml, Phoenix Pharmaceutical, Inc., St Joseph,
MO), 4 parts PBS and 1 part Xylazine (100 mg/ml, Lloyd
Laboratories, Inc., Shenandoah, IA). Body temperature was
monitored and the animals were kept on a heating pad during
the procedure as well as during the recovery period. The pupils
were dilated with drops of phenylephrine 5%/tropicamide 0.5%.
A partial retinal detachment was induced with a transscleral,
subretinal injection of ,50 mml of 1% sodium hyaluronate
(Provisc, Alcon Laboratories Inc., Fort Worth, TX), as described
previously.[8] The partial retinal detachments occupied about 40–
60% of the fundus as seen under the operating microscope. Eyes
that developed choroidal hemorrhage or significant vitreous
hemorrhage were excluded prior to analysis.
Treatment with TUDCA
Animals were treated daily with an intraperitoneal injection of
vehicle (0.15M NaHCO3) or vehicle containing TUDCA (EMD
Chemicals, Gibbstown, NJ) at a dose that has been shown safe and
effective in previous studies, 500 mg/kg body weight. [11] The pH
was adjusted to 7.4, which was allowed to dissolve at room
temperature with vortexing as needed. With the exception of
Figure 1D, all the animals received the first injection 24 hours
prior to the induction of RD. For Figure 1D, the treatment was
Figure 4. TUDCA’s effect on various caspases after RD. Assay of Caspases 2, 3, 8, and 9 activity after RD and TUDCA treatment. Treatment of
RD with TUDCA decreased the activation of caspases 2, 3 and 9 (n=6, p,0.05) but not of 8 (n=6, p.0.05).
doi:10.1371/journal.pone.0024245.g004
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vehicle injection 24 hours before the RD.
ONL thickness ratio and TUNEL stain.
The rats were euthanized 3 and 5 days after retinal detachment
induction and the eyes were enucleated and fixed in paraformal-
dehyde 4% in phosphate buffer saline (PFA-PBS) at 4uC
overnight. Then they were embedded in Optimal Cutting
Temperature media (OCT- Tissue Tek; Sakura Finetec, Tor-
rance, CA), frozen at 221uC and cut in 10mm- thick sections.
These sections were then fixed in PFA 4% for 15 minutes, prior to
staining with DAPI nuclear stain (AnaSpec/Eurogentec Group)
and Terminal dUTP Nick-End Labeling (TUNEL) staining
according to manufacturer’s instructions (Apop Tag Fluorescein
Apoptosis detection kit, Millipore, Billerica MA). Fluorescence was
imaged (DM RXA miroscope; Leica, Solms Germany) and
digitally captured. Using ImageJ image analysis software (http://
rsbweb.nih.gov/ij/), the thickness of the outer nuclear layer (ONL)
was measured in the detached as well as the attached retina. The
thicknesses were measured based on the outer boundaries of the
DAPI nuclear stain. Because the thickness of the retina seen in
cross-section varies depending on the angle of the sectioning plane
with respect to the retina, the outer nuclear layer thickness was
normalized to the thickness of the entire retina. The ‘‘normalized
ONL thickness ratio’’ is defined as the (ONL thickness/total
thickness in detached retina)/(ONL thickness/total thickness in
attached retina). Sections just posterior to the lens were used for
thickness measurements. Next, the number of TUNEL- positive
cells per mm
2 was counted in a masked fashion at the central area
of the detached retina and compared between the different
treatment groups. All measurements were performed in 12 points
of each section in 6 eyes per group.
Immunohistochemistry
In order to assess macrophage infiltration in detached retinas
(N=6 eyes per group), the sections were fixed in PFA-PBS 4%
Figure 5. TUDCA treatment does not affect endoplasmic reticulum stress and Caspase 11 levels induced by RD. Western blots (A) and
quantification (B) of CHOP expression in retinal lysates from attached and detached retinas treated with TUDCA or vehicle (administered as in
figure 1). (n=4 p,0.05 for RD vs attached). 3T3 fibroblasts and Tunicamycin (2microgram/ml for 6 hours) were used as a positive control. (C)
Quantification of Caspase 11 levels after RD and TUDCA treatment (n=6, p.0.05).
doi:10.1371/journal.pone.0024245.g005
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monoclonal antibody (Millipore, clone ED-1, #MAB1435)
overnight. After washing with PBS, the sections were incubated
with the secondary antibody Alexa Flour 488-conjugated goat
anti-mouse IgG (Invitrogen, Carlsbad,CA) for 2 hours, washed
again and mounted in Permafluor (Thermo Scientific, Fremont,
CA). The number of CD68+ cells per mm
3 was determined using
the same methods as described above for TUNEL-positive cell
quantification.
Enzyme Linked Immunosorbent Assays
Eight eyes from each group (retina attached, and retina
detached with or without treatment with TUDCA) were analyzed.
Each retina was dissected and lysed in 200 ml of protein lysis
buffer [42], sonicated for 10 seconds and then centrifuged for
5 min at 10,000 rpm, 4uC. The assays were performed on the
supernatants. For protein carbonyl content (Cell Biolabs, San
Diego, CA) and TNF-a (R&D Systems Inc., Minneapolis, MN)
assays, the samples were collected 24 hours after RD, while for
MCP-1 assays (Thermo Scientific, Rockford IL) samples were
collected both at 24 and 72 hours. To measure the concentration
of rat MCP-1, TNF-a and protein carbonyl, the retina was
sonicated in lysis buffer and equal protein extracts were used in
ELISA assays. The assays were performed according to manufac-
turer’s instructions and the results were normalized for the protein
concentration in the sample using a Bio-Rad Protein Assay Kit
(Bio-Rad Laboratories, Hercules, CA #500-0002).
Caspase 2, 3, 8, 9 Colorimetric Assay
The caspase assays were performed on the retina of animals
without retinal detahcment (n=6) as well as animals with retinal
detachment that received vehicle (n=6) or TUDCA (n=6). The
samples were stored in lysis buffer, sonicated for 10 seconds, and
centrifuged at 10,000 rpm for 5 minutes. The assay was performed
on the supernatant according to manufacturer’s instructions
(Casp-3-C and Casp-8-C for caspases 3 and 8, Sigma-Aldrich,
Saint Louis, MO; APT163 and APT173 for caspases 2 and 9,
Chemicon-Millipore, Temecula,CA) This assay is based on the
detection of a chromophore (p- nitroalanine) which is released
upon enzymatic cleavage of the labeled substrate DEVD-pNA
from the activated caspases of the cells undergoing apoptosis. The
optical density was assessed at 405nm and normalized for protein
concentration, initial optical density, and compared to a sample
filled with buffer.
Western Blotting
The vitreous and neural retina, combined, was collected on day
3 after retinal detachment. Samples were run on 4% to 12% SDS-
polyacrylamide gel electrophoresis and transferred onto PVDF
membrane. After blocking with 3% nonfat dried milk, the
membrane was reacted with a CHOP (1:1000 ; Cell Signaling,
Cat #5554S), caspase-11 (1:1000 ; Santa Cruz Biotechnology, Cat
#SC-28230). O ˆ hey were then developed with enhanced chemi-
luminescence. a ˆ-tubulin (1:1,000; Cell Signaling Technology, Cat
#2146) was used as a loading control.
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